Cost analysis of various branded versus generic chemotherapeutic agents used for the treatment of early breast cancer- a deep insight from India.

Ananth KashyapM N BalajiManik ChhabraMuhammed RashidPradeep M Muragundi

Published in: Expert review of pharmacoeconomics & outcomes research (2019)

Our evaluation inferred that substituting generic chemotherapeutic drugs can bring potential cost savings. Healthcare professionals and patients should aware and opt generic drugs to achieve goals of BC therapy.

Keyphrases

end stage renal disease
early breast cancer
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
stem cells
public health
mesenchymal stem cells
replacement therapy